Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

Overview of attention for article published in Frontiers in oncology, March 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 6,812 followers.

RT @LujanPomponio: Frontiers | Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant P…

08 Mar 2022

Reply Repost Favourite

Frontiers | Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan | Oncology https://t.co/kL7oEg8yAO

07 Mar 2022

Reply Repost Favourite

New research: Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan: Background Abiraterone and enzalutamide are widely used as first-line treatment for metastatic… https://t.c

07 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.